ZN-e4 / SciClone, Zentalis Pharma - LARVOL DELTA

A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=34 | Completed | Sponsor: Zeno Pharmaceuticals, Inc. | Phase classification: P1/2 ➔ P1

Metastases • Phase classification • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=34 | Completed | Sponsor: Zeno Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed

Trial completion • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=34 | Active, not recruiting | Sponsor: Zeno Pharmaceuticals, Inc. | N=140 ➔ 34 | Trial primary completion date: Jun 2022 ➔ Jan 2022

Enrollment change • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=140 | Active, not recruiting | Sponsor: Zeno Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021 (GlobeNewswire) - "Zentalis Pharmaceuticals, Inc...is hosting a virtual R&D Day on December 16, 2021 from 11:00 a.m. to 12:00 p.m. EST. Additional details on the event are summarized below. Zentalis’ management team along with three Key Opinion Leaders (KOLs) will present preclinical science from multiple programs and clinical updates on ZN-d5, the Company’s oral, selective BCL-2 inhibitor for hematologic malignancies, and ZN-e4, the Company’s oral EGFR inhibitor for non-small cell lung carcinoma."

Clinical data • Preclinical • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated (GlobeNewswire) - "Abemaciclib...The two separate trials will continue to enroll patients and the Company expects to report interim results in 1H 2022 from one or more of these trials....The Phase 1 monotherapy dose-escalation trial, initiated in 4Q 2020, has enrolled 14 patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) thus far in the fifth dose cohort...Patients with acute myeloid leukemia will begin enrollment in 3Q 2021. Interim results from this Phase 1 trial are expected in 1H 2022....ZN-e4 has been well-tolerated at all doses as of the March 25, 2021 data cut-off, and clinical activity was identified at doses greater than 80 mg QD. Interim results from the Phase 1/2 trial are expected in 4Q 2021."

Enrollment status • P1 data • Breast Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology

[VIRTUAL] Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer (AACR 2021) - "To overcome the T790M acquired resistance, third-generation EGFR inhibitors, such as osimertinib, were developed. Taken together, our data suggest that ZN-e4 is a potent and selective third generation EGFR inhibitor. Currently, ZN-e4 is in a Phase I clinical trial in patients with EGFR mutant NSCLC showing clinical activity and encouraging toxicity profile."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021 (GlobeNewswire) - "Zentalis Pharmaceuticals...announced that three abstracts have been accepted for presentation, including a late-breaker on its WEE1 inhibitor, ZN-c3, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021. The meeting will be held virtually on April 10-15 and May 17-21, 2021."

P1 data • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Zn-e4 (IASLC-LCTT 2020) - No abstract available

A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1; N=100; Not yet recruiting; Sponsor: Zeno Pharmaceuticals, Inc.

Clinical • New P1 trial